Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
